TCGA-UL-AAZ6-01A-11R-A41B-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 17
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.510
- MYC_TARGETS_V2+0.360
- INTERFERON_ALPHA_RESPONSE+0.310
- KRAS_SIGNALING_DN+0.280
- ESTROGEN_RESPONSE_LATE+0.250
- OXIDATIVE_PHOSPHORYLATION+0.230
- ESTROGEN_RESPONSE_EARLY+0.220
- MYC_TARGETS_V1+0.180
- GLYCOLYSIS+0.170
- DNA_REPAIR+0.150
Top 10 suppressed
- TGF_BETA_SIGNALING-0.470
- UV_RESPONSE_DN-0.460
- WNT_BETA_CATENIN_SIGNALING-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- MITOTIC_SPINDLE-0.380
- ANDROGEN_RESPONSE-0.360
- PROTEIN_SECRETION-0.360
- ALLOGRAFT_REJECTION-0.310
- NOTCH_SIGNALING-0.310
- COMPLEMENT-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GD-A6C6-01A-21R-A31N-07 | — | — | 0.813 |
| 2 | TCGA-94-7033-01A-11R-1949-07 | — | cohortSQ1 | 0.797 |
| 3 | TCGA-GU-A763-01A-11R-A32O-07 | — | — | 0.786 |
| 4 | BS_TNRHHYNC | Spinal Cord Ependymoma | — | 0.778 |
| 5 | fa9f3cc6-06eb-4cfd-8f85-9d13df39d11e | — | — | 0.777 |
| 6 | TCGA-OL-A66O-01A-11R-A31O-07 | — | B | 0.766 |
| 7 | TCGA-AO-A03T-01A-21R-A034-07 | — | B | 0.763 |
| 8 | TCGA-XF-AAN1-01A-31R-A42T-07 | — | — | 0.759 |
| 9 | SRR8518141 | — | E | 0.758 |
| 10 | 43c87798-5762-42c1-b7d8-47fc126fc2d3 | — | — | 0.754 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.510 | Cobimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.070 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.020 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |